Cage Pharma
Innovative pre-clinical biopharma advancing tumor-targeting therapies with groundbreaking encapsulated formulations for more effective cancer treatment.
Innovative pre-clinical biopharma advancing tumor-targeting therapies with groundbreaking encapsulated formulations for more effective cancer treatment.
Cage Pharma is an innovative pre-clinical biopharmaceutical startup, focusing on the development of tumor-targeting therapies with groundbreaking encapsulated formulations for more effective cancer treatment. The company's encapsulated anti-cancer agent utilizes a novel formulation of 3-bromopyruvate to target cancer by attacking tumor glycolysis, a critical feature of cancer cells. This approach allows for the effective use of the anti-cancer agent while maintaining a controlled and mild toxicity profile. Founded in 2017, Cage Pharma is headquartered in Baltimore, Maryland. The company recently secured a $137.49K Venture Round investment on 31 May 2024. Cage Pharma operates in the Biopharma, Biotechnology, and Pharmaceutical industries, positioning itself at the forefront of cutting-edge cancer treatment development.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $137.49K | - | 31 May 2024 | |
| Seed Round | $480.00K | - | 10 Jul 2019 | |
| Seed Round | $350.00K | - | 05 Jan 2018 |
No recent news or press coverage available for Cage Pharma.
We care about your data, and we'd love to use cookies make your experience better.
